25697-54-5

Upstream product

• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 140-89-6 potassium ethyl xanthogenate 

Downstream Products

• 97656-05-8 4,4',5,5'-tetramethoxy-2,2'-dithiobis(benzoic acid) 
• 79003-39-7 α-[(2-carboxy-4,5-dimethoxyphenyl)thio]-γ-butyrolactone 
• 25700-33-8 4,5-Dimethoxy-2-(3-trifluoromethyl-benzylsulfanyl)-benzoic acid 
• 97655-98-6 2-chlorosulfenyl-4,5-dimethoxybenzoyl chloride 
• 25700-55-4 4,5-Dimethoxy-2-(3-trifluoromethyl-phenylmethanesulfonyl)-benzoic acid 
• 25700-56-5 2-(4-Chloro-phenylmethanesulfonyl)-4,5-dimethoxy-benzoic acid 
• 25700-54-3 4,5-Dimethoxy-2-phenylmethanesulfonyl-benzoic acid 
• 25700-34-9 2-(4-Chloro-benzylsulfanyl)-4,5-dimethoxy-benzoic acid 
• 25697-99-8 2-Benzylsulfanyl-4,5-dimethoxy-benzoic acid 

Relevant academic research and scientific papers

NEW PHARMACEUTICAL COMPOUNDS

Compounds of formula (I), wherein R1-R4, X, Y and Z are as defined in claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.

PHARMACEUTICAL COMPOUNDS

Compounds of the formula: STR1 in which each R 1 is hydrogen, C 1-4 alkyl, C 1-4 alkoxy, halogen or nitro, and n is 0, 1, 2 or 3, R 2 is hydrogen, C 1-4 alkyl or C 2-4 alkenyl, R. sup.3 and R. sup.4 are each hydrogen, C 1-4 alkyl, optionally substituted phenyl or C. sub.6-9 cycloalkyl optionally substituted by 1 to 4 C 1-4 alkyl groups, R 5 is optionally substituted phenyl, tetrahydronaphthyl, phthalimido, saccharinyl, glutaramido, C 6-10 cycloalkyl optionally substituted with 1 to 4 C. sub.1-4 alkyl groups or a phenyl group, or C. sub.4-9 heterosubstituted cycloalkyl optionally substituted with 1 to 4 alkyl groups, x is 1, 2 or 3, y is 0 or 1 and z is 0, 1, 2 or 3; and salts thereof.The compounds are indicated for use in the treatment of disorders of the central nervous system.